{"nctId":"NCT00349336","briefTitle":"A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.","startDateStruct":{"date":"2006-08"},"conditions":["Colorectal Cancer"],"count":64,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab [Avastin]","Drug: XELOX"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab [Avastin]","Drug: FOLFOX-4"]}],"interventions":[{"name":"bevacizumab [Avastin]","otherNames":[]},{"name":"XELOX","otherNames":[]},{"name":"bevacizumab [Avastin]","otherNames":[]},{"name":"FOLFOX-4","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* adenocarcinoma of the colon or rectum, with metastatic or locally advanced disease;\n* \\>=1 target lesion.\n\nExclusion Criteria:\n\n* patients who have previously received systemic treatment for advanced or metastatic disease;\n* patients who have received adjuvant treatment for non-metastatic disease in past 3 months;\n* previous therapy with oxaliplatin or Avastin.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Time Zero to Last Measurable Plasma Concentration of Bevacizumab","description":"Area under the serum concentration-time curve from time zero to the time of the last measurable plasma concentration (AUC 0-last). Estimation of the parameter was performed using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2457.19","spread":"359.5"},{"groupId":"OG001","value":"1709.8","spread":"497.0"}]}]}]},{"type":"PRIMARY","title":"Weekly Steady-state Exposure of Bevacizumab","description":"Area under the serum concentration-time curve per week, at steady state (AUCss per week). Estimation of the parameter was performed using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4090.3","spread":"1047.6"},{"groupId":"OG001","value":"4022.4","spread":"1774.2"}]}]}]},{"type":"SECONDARY","title":"Steady-state Exposure of Bevacizumab From Time Zero to Tau","description":"Area under the serum concentration-time curve from time zero to tau, at steady state (AUCss 0-tau), where tau was the length of the cycle, i.e., tau = 3 weeks for XELOX+BV and tau = 2 weeks for FOLFOX-4+BEV. Estimation of the parameter was performed using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2457.0","spread":"360.6"},{"groupId":"OG001","value":"1758.4","spread":"468.5"}]}]}]},{"type":"SECONDARY","title":"Maximum Serum Concentration of Bevacizumab at Steady State","description":"Maximum serum concentration at steady state (Css,max). Estimation of the parameter was performed using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"242","spread":"31.6"},{"groupId":"OG001","value":"215.6","spread":"53.2"}]}]}]},{"type":"SECONDARY","title":"Minimum Serum Concentration of Bevacizumab at Steady State","description":"Minimum serum concentration at steady state (Css, min). Estimation of the parameter was performed using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":"14.1"},{"groupId":"OG001","value":"80.0","spread":"25.5"}]}]}]},{"type":"SECONDARY","title":"Serum Clearance of Bevacizumab","description":"Serum clearance (CL). Estimation of the parameter was performed using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.236","spread":"0.051"},{"groupId":"OG001","value":"0.226","spread":"0.056"}]}]}]},{"type":"SECONDARY","title":"Time of Maximum Serum Concentration of Bevacizumab","description":"Time of maximum serum concentration (tmax). Estimation of the parameter was performed using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.442","spread":"6.786"},{"groupId":"OG001","value":"4.958","spread":"3.596"}]}]}]},{"type":"SECONDARY","title":"Volume of Distribution of Bevacizumab at Steady State","description":"Volume of distribution at steady state (Vss). Estimation of the parameter was performed using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.932","spread":"1.409"},{"groupId":"OG001","value":"4.908","spread":"1.563"}]}]}]},{"type":"SECONDARY","title":"Terminal Half-life of Bevacizumab","description":"Terminal half-life (t1/2) (apparent elimination half-life). Estimation of the parameter was performed using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"381.2","spread":"91.7"},{"groupId":"OG001","value":"394.1","spread":"121.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":32},"commonTop":["Fatigue","Diarrhoea","Nausea","Peripheral Sensory Neuropathy","Neuropathy Peripheral"]}}}